A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis

Summary

This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled study with an open-label extension to evaluate the efficacy and safety of camoteskimab in adults with moderate to severe AD.

Timeline

Start

2024-05-01

Primary completion

2025-03-26

Completion

2025-08-12

Outcome

Met primary endpoint

release “Apollo Therapeutics’ Anti-IL-18 Antibody Camoteskimab Met the Primary Endpoint in a Double-Blind, Randomized, Placebo-Controlled Phase 2a Clinical Trial in Atopic Dermatitis” apollotx.com ↗

Drugs

Indications